|Bid||88.79 x 3100|
|Ask||89.32 x 1800|
|Day's Range||89.02 - 90.58|
|52 Week Range||61.13 - 93.04|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||40.99|
|Forward Dividend & Yield||0.72 (0.81%)|
|Ex-Dividend Date||Jun. 29, 2020|
|1y Target Est||N/A|
Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system. Both deliver even faster detection of target compounds providing customers increased sample throughput and reduced time to generate results. The instruments are being introduced at ASMS 2020 Reboot, the interactive, online version of the annual conference of the American Society for Mass Spectrometry, being held June 1-12, 2020.
Agilent Technologies Inc. (NYSE: A) announces that biotech startup Trilogy Sciences has been awarded an Agilent Golden Ticket at LabCentral, a leading biotech innovation hub based in Cambridge, Massachusetts. LabCentral is a shared laboratory space designed as a launchpad for high-potential life sciences and biotech startups. The Golden Ticket provides funding of one lab bench space for a year.
Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration has approved the company’s PD-L1 IHC 22C3 pharmDx as a companion diagnostic (CDx) to identify patients with non-small cell lung cancer who are appropriate for first-line monotherapy with KEYTRUDA (pembrolizumab) on the Dako Omnis platform.
Agilent Technologies Inc. (NYSE: A) announced today that it has become a top-level sponsor of My Green Lab, a nonprofit organization dedicated to improving the sustainability of scientific research.
Agilent provides update on COVID-19 impact and sets second-quarter earnings call for May 21.
Agilent Technologies Inc. (NYSE: A) today announced the launch of the newest instrument in its Raman technology portfolio. The new Agilent Vaya Raman raw material identity verification system is a handheld instrument that accelerates quality control testing in the pharmaceutical and biopharmaceutical industries.
Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.
Agilent Technologies Inc. (NYSE: A) announced today an extension to its digital lab capabilities with Agilent CrossLab Asset Monitoring, an advanced service for laboratories seeking increased visibility and control over operations.
Agilent Technologies Inc. (NYSE: A) today announced that two of the company’s instruments have received Scientists’ Choice awards. The Agilent 8890 GC system won for Best New Separations Product, and the Agilent InfinityLab LC/MSD iQ system won for Best New Spectroscopy Product.
Agilent Technologies Inc. (NYSE: A) today introduced three new microarrays to meet the needs of cytogenetic laboratories conducting both prenatal and postnatal research.
Agilent Technologies Inc. (NYSE: A) and Visiopharm today announced that they have entered a co-marketing agreement. The announcement is happening at the USCAP 109th Annual Meeting being held February 29 through March 5, 2020, in Los Angeles, CA.